Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Core Insights - Clene Inc. announced new preclinical data indicating that CNM-Au8® improves cellular health in a dopaminergic neuron model of Parkinson's disease, showcasing its potential therapeutic benefits [1][4][6] Group 1: Study Details - The study utilized skin cells from 8 sporadic PD patients, 14 familial PD patients, and 13 healthy individuals, converting them into dopaminergic neurons to study disease processes [2] - The innovative model retains age-related characteristics, allowing for a more accurate representation of Parkinson's disease [2] Group 2: Key Findings - CNM-Au8 treatment improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized dysregulated gene expression in both familial and sporadic Parkinson's disease [4][5] - Specifically, CNM-Au8 increased mitochondrial health and volume while reducing harmful reactive oxygen species in familial PD neurons, with milder effects in sporadic PD neurons [5] - The treatment also lowered levels of inflammatory proteins in sporadic PD neurons, contributing to reduced neuroinflammation [5] - CNM-Au8 increased the NAD+/NADH ratio, correcting intracellular metabolite levels in both familial and sporadic PD neurons [5] - The treatment normalized gene expression profiles in PD neurons, bringing them closer to control levels [5] Group 3: Safety and Future Development - CNM-Au8 demonstrated a favorable safety profile, showing no toxicity towards dopaminergic cells at all tested doses, consistent with clinical observations from previous studies [5] - Clene is advancing CNM-Au8 through late-stage clinical studies for ALS and plans to design a Phase 2 clinical study for Parkinson's disease [6]